pyrazinamide has been researched along with Acute Liver Injury, Drug-Induced in 204 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pyrazinamide (PZA) is an important component of a standard combination therapy against tuberculosis." | 9.12 | Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug. ( Hussain, Z; Ma, X; Zhu, J, 2021) |
| "To compare the incidence of severe hepatitis in HIV-infected patients receiving rifampicin plus pyrazinamide (RZ) for antituberculosis prophylaxis with that of patients receiving a conventional isoniazid-based regime for 6 to 12 months (6-12H)." | 8.86 | [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials]. ( Camacho, A; Castón, JJ; Gallo, M; García-Lázaro, M; Kindelán, JM; Natera, C; Pérez-Camacho, I; Rivero, A; Torre-Cisneros, J, 2010) |
| "We mimicked the concentration-time profiles achieved by human equivalent doses of moxifloxacin 800 mg/day, rifampin 1800 mg/day, and pyrazinamide 4000 mg/day (high-dose regimen) vs isoniazid 300 mg/day, rifampin 600 mg/day, and pyrazinamide 2000 mg/day (standard therapy) in bactericidal and sterilizing effect studies in the hollow fiber system model of tuberculosis (HFS-TB)." | 7.88 | Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet! ( Deshpande, D; Gumbo, T; Magombedze, G; Srivastava, S, 2018) |
| "To investigate the clinical characteristics, adverse drug reactions, and outcomes of the oldest old patients (aged ≥80 years) with tuberculosis (TB) treated with rifampicin, isoniazid, and pyrazinamide (RIP)-containing regimens." | 7.83 | The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide. ( Chang, PJ; Cheng, CW; Chou, YL; Lin, HS; Lin, JC; Lin, MS; Ye, JJ, 2016) |
| "Severe liver injuries were attributed to the rifampin and pyrazinamide (RZ) regimen after it was recommended for treating latent tuberculosis infection." | 7.73 | Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. ( Bower, WA; Castro, KG; Iademarco, MF; Ijaz, K; Jereb, JA; Lambert, LA; McElroy, PD; Navin, TR; Spradling, PR, 2006) |
| "We conducted a survey of state and city tuberculosis programs and other health care settings in the United States where rifampin-pyrazinamide was prescribed." | 7.73 | National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. ( Castro, KG; Iademarco, MF; Ijaz, K; Jereb, JA; Lambert, LA; McElroy, PD; Navin, TR, 2005) |
| "The case of a 30-y-old male with latent tuberculosis who developed chemical hepatitis requiring hospitalization after 50 d of treatment with rifampin and pyrazinamide is reported." | 7.73 | Rifampin plus pyrazinamide-induced hepatitis requiring hospitalization in a 30-y-old male with latent tuberculosis. ( Mantadakis, E; Potolidis, E; Samonis, G; Zeniodi, MH, 2005) |
| "An alternative regimen for the treatment of latent tuberculosis infection is 2 months of rifampin and pyrazinamide, but some patients have died of hepatitis associated with this therapy." | 7.72 | Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. ( Cheng, AC; Engemann, JJ; Fortenberry, ER; Hamilton, CD; Stout, JE, 2003) |
| "Preventive treatment with rifampin-pyrazinamide causes severe hepatotoxicity more often than does preventive treatment with isoniazid or curative treatment for tuberculosis." | 7.72 | Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. ( Baars, H; Borgdorff, M; Cobelens, F; Kalisvaart, N; Keizer, S; Kik, S; Mensen, M; Trompenaars, MC; van Gerven, P; van Hest, R, 2004) |
| "CDC has reported previously surveillance data of severe liver injury in patients treated for latent tuberculosis infection (LTBI) with a daily and twice-weekly 2-month regimen of rifampin with pyrazinamide (RZ)." | 7.72 | Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. ( , 2003) |
| "In 2000, results of a multinational trial demonstrated that a 2-month course of rifampin and pyrazinamide (RZ) was as effective as isoniazid (INH) in reducing tuberculosis in human immunodeficiency virus (HIV)-infected individuals with latent tuberculosis infection (LTBI)." | 7.72 | Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? ( Chaisson, RE; Cohn, DL; Gordin, FM; Matts, JP; O'Brien, RJ, 2004) |
| "Reports of fatal and severe liver injury associated with treatment of latent tuberculosis infection (LTBI) with the drug combination rifampin and pyrazinamide (RZ) prompted CDC to issue revised guidelines for the use of this regimen on August 31, 2001." | 7.71 | Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. ( , 2002) |
| "During February 12-August 24, 2001, a total of 21 cases of liver injury associated with a 2-month rifampin-pyrazinamide (RIF-PZA) regimen for the treatment of latent tuberculosis infection (LTBI) was reported to CDC." | 7.71 | Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001. ( , 2001) |
| "One of the recommended treatments for latent tuberculosis infection (LTBI) is a 9-month regimen of isoniazid (INH); a 2-month regimen of rifampin (RIF) and pyrazinamide (PZA) is an alternative in some instances." | 7.71 | Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000. ( , 2001) |
| "Noncaseating granulomatous hepatitis may be caused by a variety of drugs, but we have not found, by computer search of the literature, a previous describe of granulomatous hepatitis associated with pyrazinamide." | 7.69 | Pyrazinamide-induced granulomatous hepatitis. ( Buyanowsky, G; Dan, M; Knobel, B; Zaidel, L, 1997) |
| "Results are presented of the incidence of hepatitis, nearly always with jaundice, among 1686 patients in clinical trials of the treatment of spinal tuberculosis, of tuberculosis meningitis and of pulmonary tuberculosis with short-course regimens containing rifampicin, isoniazid, streptomycin and pyrazinamide." | 7.67 | Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. ( Janardhanam, B; Parthasarathy, R; Ramachandran, P; Santha, T; Sarma, GR; Sivasubramanian, S; Somasundaram, PR; Tripathy, SP, 1986) |
| " According to the findings of the present study, all 3 of the potentially hepatotoxic drugs (isoniazid, rifampicin, and pyrazinamide) can be reintroduced simultaneously at full dosage safely from day 1, especially for patients with bilateral extensive pulmonary tuberculosis, to halt disease transmission or to treat patients with life-threatening tuberculosis." | 5.14 | Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. ( Jayaswal, A; Makharia, G; Mohan, A; Sarda, P; Sharma, SK; Singh, S; Singla, R; Sreenivas, V, 2010) |
| "Pyrazinamide (PZA) is an important component of a standard combination therapy against tuberculosis." | 5.12 | Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug. ( Hussain, Z; Ma, X; Zhu, J, 2021) |
| "To compare the incidence of severe hepatitis in HIV-infected patients receiving rifampicin plus pyrazinamide (RZ) for antituberculosis prophylaxis with that of patients receiving a conventional isoniazid-based regime for 6 to 12 months (6-12H)." | 4.86 | [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials]. ( Camacho, A; Castón, JJ; Gallo, M; García-Lázaro, M; Kindelán, JM; Natera, C; Pérez-Camacho, I; Rivero, A; Torre-Cisneros, J, 2010) |
| "The cornerstone of tuberculosis management is a 6-month course of isoniazid, rifampicin, pyrazinamide and ethambutol." | 4.84 | Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. ( Aarnoutse, RE; Boeree, MJ; de Lange, WC; Dekhuijzen, R; Tostmann, A; van der Ven, AJ, 2008) |
| "Isoniazid, pyrazinamide and rifampicin have hepatotoxic potential, and can lead to such reactions during antituberculosis chemotherapy." | 4.83 | Antituberculosis drugs and hepatotoxicity. ( Leung, CC; Yew, WW, 2006) |
| "In order to determine the characteristics of drug-induced liver injury (DILI), adult patients diagnosed with tuberculosis and with an anti-tuberculosis treatment scheme including pyrazinamide were studied." | 3.96 | Clinical characteristics of pyrazinamide-associated hepatotoxicity in patients at a hospital in Lima, Peru. ( Amado, J; Moscol, S; Oscanoa, T, 2020) |
| "We mimicked the concentration-time profiles achieved by human equivalent doses of moxifloxacin 800 mg/day, rifampin 1800 mg/day, and pyrazinamide 4000 mg/day (high-dose regimen) vs isoniazid 300 mg/day, rifampin 600 mg/day, and pyrazinamide 2000 mg/day (standard therapy) in bactericidal and sterilizing effect studies in the hollow fiber system model of tuberculosis (HFS-TB)." | 3.88 | Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet! ( Deshpande, D; Gumbo, T; Magombedze, G; Srivastava, S, 2018) |
| "We prospectively examined the incidence of drug-induced hepatitis in 2070 patients treated for TB with the standard regimen based on 6 months of rifampicin (R, RMP) and isoniazid (H, INH), with 2 months of initial pyrazinamide (Z, PZA) and ethambutol (E, EMB), over a 30-year period from 1981 to 2010, in Blackburn, UK." | 3.83 | Drug-related hepatitis in patients treated with standard anti-tuberculosis chemotherapy over a 30-year period. ( Bright-Thomas, RJ; Gondker, AR; Morris, J; Ormerod, LP, 2016) |
| "To investigate the clinical characteristics, adverse drug reactions, and outcomes of the oldest old patients (aged ≥80 years) with tuberculosis (TB) treated with rifampicin, isoniazid, and pyrazinamide (RIP)-containing regimens." | 3.83 | The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide. ( Chang, PJ; Cheng, CW; Chou, YL; Lin, HS; Lin, JC; Lin, MS; Ye, JJ, 2016) |
| "To compare the free and total plasma drug concentrations of rifampicin (RMP), isoniazid and pyrazinamide in subjects with or without anti-tuberculosis drug-induced hepatotoxicity (DIH)." | 3.80 | Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. ( Biswas, A; Makharia, GK; Satyaraddi, A; Sharma, A; Sharma, SK; Singh, S; Sinha, S; Sirohiwal, A; Velpandian, T; Vishnubhatla, S, 2014) |
| "A case-control study including Caucasian patients with tuberculosis (TB) treated with isoniazid, rifampicin and pyrazinamide." | 3.77 | N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. ( Agúndez, JA; Botana-Rial, M; Constenla, L; Fernández-Villar, A; Leiro-Fernandez, V; Valverde, D; Vázquez-Gallardo, R, 2011) |
| "We conducted a survey of state and city tuberculosis programs and other health care settings in the United States where rifampin-pyrazinamide was prescribed." | 3.73 | National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. ( Castro, KG; Iademarco, MF; Ijaz, K; Jereb, JA; Lambert, LA; McElroy, PD; Navin, TR, 2005) |
| "To determine whether inactive hepatitis B surface antigen (HBsAg) carriers are at a higher risk of drug-induced hepatotoxicity than control subjects during antituberculosis treatment with standard short-course regimens of isoniazid, rifampin, ethambutol, and/or pyrazinamide." | 3.73 | Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. ( Choi, MS; Chung, MP; Kim, H; Koh, WJ; Kwon, OJ; Lee, BH; Suh, GY, 2005) |
| "The case of a 30-y-old male with latent tuberculosis who developed chemical hepatitis requiring hospitalization after 50 d of treatment with rifampin and pyrazinamide is reported." | 3.73 | Rifampin plus pyrazinamide-induced hepatitis requiring hospitalization in a 30-y-old male with latent tuberculosis. ( Mantadakis, E; Potolidis, E; Samonis, G; Zeniodi, MH, 2005) |
| "Severe liver injuries were attributed to the rifampin and pyrazinamide (RZ) regimen after it was recommended for treating latent tuberculosis infection." | 3.73 | Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. ( Bower, WA; Castro, KG; Iademarco, MF; Ijaz, K; Jereb, JA; Lambert, LA; McElroy, PD; Navin, TR; Spradling, PR, 2006) |
| " Although the overall risk of hepatotoxicity in patients receiving pyrazinamide and rifampin daily for the treatment of latent tuberculosis infection was higher, liver functions returned to normal after the medications were discontinued." | 3.73 | Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection. ( Cook, PP; Holbert, D; Maldonado, RA; Yarnell, CT, 2006) |
| "An alternative regimen for the treatment of latent tuberculosis infection is 2 months of rifampin and pyrazinamide, but some patients have died of hepatitis associated with this therapy." | 3.72 | Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. ( Cheng, AC; Engemann, JJ; Fortenberry, ER; Hamilton, CD; Stout, JE, 2003) |
| "CDC has reported previously surveillance data of severe liver injury in patients treated for latent tuberculosis infection (LTBI) with a daily and twice-weekly 2-month regimen of rifampin with pyrazinamide (RZ)." | 3.72 | Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. ( , 2003) |
| "In 2000, results of a multinational trial demonstrated that a 2-month course of rifampin and pyrazinamide (RZ) was as effective as isoniazid (INH) in reducing tuberculosis in human immunodeficiency virus (HIV)-infected individuals with latent tuberculosis infection (LTBI)." | 3.72 | Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? ( Chaisson, RE; Cohn, DL; Gordin, FM; Matts, JP; O'Brien, RJ, 2004) |
| "Two months of rifampin and pyrazinamide (RIF/PZA) for tuberculosis prevention has been advocated as a way to improve adherence in mobile populations, such as recent immigrants." | 3.72 | Tuberculosis prevention in Mexican immigrants: limitations of short-course therapy. ( Carroll, MR; Dworkin, MS; Kandula, NR; Lauderdale, DS, 2004) |
| "Preventive treatment with rifampin-pyrazinamide causes severe hepatotoxicity more often than does preventive treatment with isoniazid or curative treatment for tuberculosis." | 3.72 | Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. ( Baars, H; Borgdorff, M; Cobelens, F; Kalisvaart, N; Keizer, S; Kik, S; Mensen, M; Trompenaars, MC; van Gerven, P; van Hest, R, 2004) |
| "Reports of fatal and severe liver injury associated with treatment of latent tuberculosis infection (LTBI) with the drug combination rifampin and pyrazinamide (RZ) prompted CDC to issue revised guidelines for the use of this regimen on August 31, 2001." | 3.71 | Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. ( , 2002) |
| "One of the recommended treatments for latent tuberculosis infection (LTBI) is a 9-month regimen of isoniazid (INH); a 2-month regimen of rifampin (RIF) and pyrazinamide (PZA) is an alternative in some instances." | 3.71 | Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000. ( , 2001) |
| "During February 12-August 24, 2001, a total of 21 cases of liver injury associated with a 2-month rifampin-pyrazinamide (RIF-PZA) regimen for the treatment of latent tuberculosis infection (LTBI) was reported to CDC." | 3.71 | Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001. ( , 2001) |
| "Isoniazid prophylaxis for 12 months effectively prevents tuberculosis in HIV-infected persons and may decrease the incidence of other HIV-related disease and mortality." | 3.70 | Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis. ( Rose, DN, 1998) |
| "Noncaseating granulomatous hepatitis may be caused by a variety of drugs, but we have not found, by computer search of the literature, a previous describe of granulomatous hepatitis associated with pyrazinamide." | 3.69 | Pyrazinamide-induced granulomatous hepatitis. ( Buyanowsky, G; Dan, M; Knobel, B; Zaidel, L, 1997) |
| "Results are presented of the incidence of hepatitis, nearly always with jaundice, among 1686 patients in clinical trials of the treatment of spinal tuberculosis, of tuberculosis meningitis and of pulmonary tuberculosis with short-course regimens containing rifampicin, isoniazid, streptomycin and pyrazinamide." | 3.67 | Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. ( Janardhanam, B; Parthasarathy, R; Ramachandran, P; Santha, T; Sarma, GR; Sivasubramanian, S; Somasundaram, PR; Tripathy, SP, 1986) |
| " In conclusion, regimen including PZA seems to be safe for late elderly patients with pulmonary TB." | 2.90 | Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study. ( Asaoka, M; Baba, T; Hagiwara, E; Katano, T; Kitamura, H; Komatsu, S; Ogura, T; Okuda, R; Sekine, A; Suido, Y, 2019) |
| "Pyrazinamide was used in addition to isoniazid and rifampicin in a significantly higher percentage of patients in the ATT-induced hepatitis group (70%) as compared with those in the control group (42%)." | 2.68 | Antituberculosis treatment-induced hepatotoxicity: role of predictive factors. ( Arora, A; Garg, PK; Pande, JN; Singh, J; Tandon, RK; Thakur, VS, 1995) |
| " tuberculosis were treated in the initial phase as inpatients for 2-3 months at random with either pyrazinamide (Z) or ethambutol (E) in combination with isoniazid (H) and rifampicin (R)." | 2.66 | [Which is the best drug combination for the short-term therapy of tuberculosis? A prospective randomized study with 190 patients]. ( Bezel, R; Brändli, O; Häcki, M; Karrer, W; Röthlisberger, K; Rubin, S, 1985) |
| " In a controlled study of culture-positive advanced pulmonary tuberculosis we have compared treatment regimens with PZA in a dosage of less than 2 g and with ethambutol (EMB)." | 2.65 | [Pyrazinamide versus ethambutol in short-term therapy of lung tuberculosis. A randomized study]. ( Brändli, O; Fiala, W; Häcki, MA, 1983) |
| "Treatment of latent tuberculosis infection (LTBI) is an important component of tuberculosis (TB) control, and this study updates a previous network meta-analysis of the best LTBI treatment options to inform public health action and programmatic management of LTBI." | 2.55 | Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis. ( Beer, N; Harris, RJ; Lipman, MC; Stagg, HR; van der Werf, MJ; Zenner, D, 2017) |
| "Effective treatment of latent tuberculosis infection (LTBI) is an important component of TB elimination programs." | 2.50 | Treatment of latent tuberculosis infection: a network meta-analysis. ( Abubakar, I; Harris, RJ; Lipman, MC; Muñoz, L; Stagg, HR; Zenner, D, 2014) |
| "About 97% of patients with pulmonary tuberculosis became bacteriologically quiescent by the 12 months of streptomycin, para-aminosalicylate and isoniazid." | 2.41 | [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients]. ( Wada, M, 2001) |
| " Prescribed at a daily dosage of 30 to 35 mg/kg (1,5 to 2 g daily), it gives no major side effects." | 2.36 | [Toxicity of pyrazinamide in antituberculous treatments (author's transl)]. ( Perdrizet, S; Pretet, S, 1980) |
| "Anti-tuberculosis drug-induced hepatotoxicity (ATDH) is a serious adverse reaction to anti-tuberculosis (TB) treatment." | 1.43 | Association between TXNRD1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a prospective study. ( He, JQ; Ji, GY; Liu, QQ; Sandford, AJ; Wang, Y; Wu, JC; Wu, SQ; Zhang, MM, 2016) |
| "Pyrazinamide (PZA) is an indispensable first-line drug used for the treatment of tuberculosis which may cause serious hepatotoxicity; however, the mechanisms underlying these toxicities are poorly understood." | 1.43 | Pyrazinamide Induced Rat Cholestatic Liver Injury through Inhibition of FXR Regulatory Effect on Bile Acid Synthesis and Transport. ( Ding, PP; Dong, SZ; Guo, HL; Hassan, HM; Jiang, ZZ; Sun, LX; Wang, T; Zhang, LY; Zhang, Y, 2016) |
| " Due to hepatotoxicity worries, there are no dose-response studies in children." | 1.43 | A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies. ( Cirrincione, KN; Crosswell, HE; Deshpande, D; Gumbo, T; Pasipanodya, JG; Ramachandran, G; Sherman, CM; Shuford, S; Srivastava, S; Swaminathan, S, 2016) |
| "Gastrointestinal events, hepatitis, hearing impairment, arthralgia, psychosis, hypothyroidism, visual disturbances, giddiness, peripheral neuropathy, skin reactions, swelling or pain at injection site, anorexia and sleep disturbances were important amongst these." | 1.40 | Profile of adverse drug reactions in drug resistant tuberculosis from Punjab. ( Bharti, H; Bhushan, B; Chander, R; Gupta, A; Kajal, NC; Ranga, V, 2014) |
| " PA and 5-OH-PA are more toxic than PZA." | 1.39 | A novel mechanism underlies the hepatotoxicity of pyrazinamide. ( Chang, WL; Hu, OY; Pai, CY; Shih, TY; Wang, NC; Yang, P, 2013) |
| "[Methods] Thirty-six patients with pulmonary tuberculosis, who were admitted to Yokohama City University Hospital between June 2011 and March 2012 were included." | 1.39 | [Comparison of drug-induced hepatitis occurring in elderly and younger patients during anti-tuberculosis treatment with a regimen including pyrazinamide]. ( Horita, N; Ishigatsubo, Y; Miyazawa, N; Sasaki, M; Takahashi, R; Tomaru, K; Tsukahara, T, 2013) |
| "Pyrazinamide (PZA) is an important sterilizing prodrug that shortens the duration of tuberculosis therapy." | 1.39 | Gene expression profiling reveals potential key pathways involved in pyrazinamide-mediated hepatotoxicity in Wistar rats. ( Chen, M; Jiang, Z; Li, F; Liu, L; Su, Y; Sun, L; Wang, Y; Zhang, L; Zhang, S; Zhang, Y, 2013) |
| "Hepatotoxicity is one of the most frequent adverse events occurring during tuberculosis treatment that may negatively affect treatment compliance, clinical outcome." | 1.38 | Management of and risk factors related to hepatotoxicity during tuberculosis treatment. ( Ağca, S; Arda, H; Babalık, A; Bakırcı, N; Calışır, HC; Cetintaş, G; Kızıltaş, S; Oruç, K, 2012) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "A 54-year-old woman was admitted for pleural tuberculosis diagnosed by right chest pain and cough." | 1.37 | A case of isoniazid-induced liver injury diagnosed by use of the DLST, and successful reintroduction of isoniazid for pleural tuberculosis. ( Fujita, M; Ikegame, S; Kajiki, A; Nakanishi, Y; Wakamatsu, K, 2011) |
| " An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems." | 1.36 | Developing structure-activity relationships for the prediction of hepatotoxicity. ( Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010) |
| "Pretreatment with caffeine, nicotinic acid or non-substituted pyrazinoic acid activated the LPS/D-GalN induced elevation of plasma IL-10 levels at 1 and 2 h, although there were no statistically significant differences in IL-10 levels between control and nicotinic acid or non-substituted pyrazinoic acid treated rats." | 1.35 | Protective effects of coffee-derived compounds on lipopolysaccharide/D-galactosamine induced acute liver injury in rats. ( Akashi, I; Hirano, T; Kagami, K; Oka, K, 2009) |
| " Metabolism and the formation of toxic metabolites of the TB drugs may play an important role in the development of ATDH." | 1.35 | Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity. ( Aarnoutse, RE; Boeree, MJ; Dekhuijzen, PN; Peters, WH; Roelofs, HM; Tostmann, A; van der Ven, AJ, 2008) |
| "4%) who had a drug-related adverse event." | 1.33 | Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. ( Bock, NN; Grabau, JC; Jasmer, RM; Lobato, MN; Reves, RR; Shang, N, 2005) |
| "Nebulization of nanoparticles-based ATDs forms a sound basis for improving drug bioavailability and reducing the dosing frequency for better management of pulmonary tuberculosis." | 1.32 | Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. ( Khuller, GK; Pandey, R; Prasad, B; Sharma, A; Sharma, S; Zahoor, A, 2003) |
| "Major adverse reactions to antituberculosis drugs can cause significant morbidity, and compromise treatment regimens for tuberculosis (TB)." | 1.32 | Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. ( Menzies, D; Parisien, I; Pelletier, M; Rocher, I; Valiquette, C; Yee, D, 2003) |
| "Hydrocephalus was common (28 of 41 tested), but only 8 (15." | 1.31 | [Central nervous system tuberculosis in children: 2. Treatment and outcome]. ( Gusmão Filho, FA; Marques, HH; Marques-Dias, MJ; Ramos, SR, 2001) |
| "Out of 1128 new pulmonary tuberculosis patients, six-hundred twenty started treatment with six-month (2HRZS or E/4HRE) in Fukujuji Hospital, JATA, in Tokyo from January 1991 to December 1996." | 1.30 | [Six-months chemotherapy (2HRZS or E/4HRE) of new cases of pulmonary tuberculosis--six year experiences on its effectiveness, toxicity, and acceptability]. ( Ito, K; Mizutani, S; Ogata, H; Sugita, H; Wada, M; Yoshiyama, T, 1999) |
| "Pyrazinamide appeared to increase the hepatotoxicity of isoniazid and rifampicin." | 1.29 | Anti tubercular treatment induced hepatotoxicity: does acetylator status matter? ( Garg, PK; Singh, J; Tandon, RK; Thakur, VS, 1995) |
| "Four patients presented hepatic encephalopathy." | 1.29 | [Severe hepatotoxicity of tuberculostatic agents. Increase in the incidence]. ( Bruguera, M; Mas, A; Moitinho, E; Rodés, J; Salmerón, JM, 1996) |
| "Twenty-nine patients with extensive pulmonary tuberculosis and drug-induced hepatitis were treated with ofloxacin along with other relatively non-hepatotoxic drugs, either during the interim phase to await recovery of liver function in some, or as definitive therapy as required by the compromised hepatic status of others." | 1.28 | Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction. ( Kwan, SY; Lee, J; Wong, PC; Yew, WW, 1992) |
| "In Zimbabwe patients with pulmonary tuberculosis who are acid-fast bacilli (AFB) negative in the sputum are treated in the two month intensive phase with isoniazid, thiacetazone pyrazinamide and streptomycin (regimen A)." | 1.28 | Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population. ( Kusema, T; Mhonda, M; Neill, P; Nhachi, CF; Pringle, D, 1990) |
| "We investigated the pharmacokinetic interaction of RMP (administered from the first day of treatment onwards), PZA (given from the second day onwards), and INH (day 17 onwards) in ten, previously untreated patients with pulmonary tuberculosis (five slow acetylators and five fast acetylators)." | 1.28 | [Clinico-pharmacokinetic interactions of rifampicin, pyrazinamide and isoniazide]. ( Loos, U; Musch, E; Schwabe, HK, 1990) |
| "When pyrazinamide was used in combination with isoniazid or rifampicin a marked increase in the activity of aspartate and alanine aminotransferases in blood serum and induction of lipid peroxidation in the liver were observed in addition to the disorders in cholopoiesis and lowering of the reduced glutathion levels." | 1.28 | [Hepatotoxic effect of a combination of pyrazinamide with isoniazid and rifampicin]. ( Klimniuk, EV; Slivka, IuI; Tabachuk, OE, 1989) |
| " Minor adverse reactions occurred with similar frequencies during daily (5%) and intermittent (5%) treatment but in no case was modification of rifampicin dosage required." | 1.27 | Safety of thrice-weekly rifampicin for tuberculosis in South-East Asian refugees. ( McKenzie, DK; Mukerjee, CM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 53 (25.98) | 18.7374 |
| 1990's | 28 (13.73) | 18.2507 |
| 2000's | 57 (27.94) | 29.6817 |
| 2010's | 53 (25.98) | 24.3611 |
| 2020's | 13 (6.37) | 2.80 |
| Authors | Studies |
|---|---|
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Greene, N | 1 |
| Fisk, L | 1 |
| Naven, RT | 1 |
| Note, RR | 1 |
| Patel, ML | 1 |
| Pelletier, DJ | 1 |
| Ekins, S | 1 |
| Williams, AJ | 1 |
| Xu, JJ | 1 |
| Chen, M | 3 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 3 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| Wen, Y | 1 |
| Zhang, G | 1 |
| Wu, X | 1 |
| Wang, YC | 1 |
| Chen, KH | 1 |
| Chen, YL | 1 |
| Lin, SW | 1 |
| Liu, WD | 1 |
| Wang, JT | 1 |
| Hung, CC | 1 |
| Ezhilarasan, D | 1 |
| Bakshi, S | 1 |
| Kaur, M | 1 |
| Verma, A | 1 |
| Sharma, S | 3 |
| Liu, X | 2 |
| Ma, Y | 1 |
| Liu, Y | 1 |
| Li, Q | 1 |
| Zhang, H | 1 |
| Fu, S | 1 |
| Chen, S | 1 |
| Li, H | 1 |
| Li, S | 1 |
| Hou, P | 1 |
| Bai, H | 1 |
| Wu, T | 1 |
| Jiao, L | 1 |
| Wu, Q | 1 |
| Zhao, Z | 1 |
| Song, J | 2 |
| Liu, T | 1 |
| Lv, Y | 1 |
| Lu, X | 1 |
| Ying, B | 1 |
| Zhao, H | 1 |
| Wang, Y | 5 |
| Zhang, T | 1 |
| Wang, Q | 3 |
| Xie, W | 1 |
| Liu, L | 3 |
| Li, X | 1 |
| Huang, C | 2 |
| Bian, Y | 2 |
| Cao, J | 2 |
| Qu, W | 1 |
| Miao, L | 2 |
| Goh, ZH | 1 |
| Tee, JK | 1 |
| Ho, HK | 1 |
| Bourhia, M | 1 |
| Ullah, R | 1 |
| S Alqahtani, A | 1 |
| Ibenmoussa, S | 1 |
| Oscanoa, T | 1 |
| Moscol, S | 1 |
| Amado, J | 1 |
| Sharma, V | 1 |
| Kaur, R | 1 |
| Sharma, VL | 1 |
| Hussain, Z | 1 |
| Zhu, J | 1 |
| Ma, X | 1 |
| Xiang, X | 1 |
| Wu, SQ | 3 |
| Chen, G | 2 |
| Zhang, MM | 3 |
| Wang, MG | 1 |
| Wang, FJ | 1 |
| Sandford, AJ | 2 |
| He, JQ | 3 |
| Rawat, A | 1 |
| Chaturvedi, S | 1 |
| Singh, AK | 1 |
| Guleria, A | 1 |
| Dubey, D | 1 |
| Keshari, AK | 1 |
| Raj, V | 1 |
| Rai, A | 1 |
| Prakash, A | 1 |
| Kumar, U | 1 |
| Kumar, D | 1 |
| Saha, S | 1 |
| Zenner, D | 2 |
| Beer, N | 1 |
| Harris, RJ | 2 |
| Lipman, MC | 2 |
| Stagg, HR | 2 |
| van der Werf, MJ | 1 |
| Feng, M | 1 |
| Wu, JC | 2 |
| Ji, GY | 2 |
| Liu, QQ | 2 |
| Mi, Y | 1 |
| Shi, C | 1 |
| Ye, Z | 1 |
| Srivastava, S | 2 |
| Deshpande, D | 2 |
| Magombedze, G | 1 |
| Gumbo, T | 2 |
| Hagiwara, E | 1 |
| Suido, Y | 1 |
| Asaoka, M | 1 |
| Katano, T | 1 |
| Okuda, R | 1 |
| Sekine, A | 1 |
| Kitamura, H | 1 |
| Baba, T | 1 |
| Komatsu, S | 1 |
| Ogura, T | 1 |
| Hussain, T | 1 |
| Gupta, RK | 1 |
| K, S | 1 |
| Khan, MS | 1 |
| Hussain, MD | 1 |
| Arif, MD | 1 |
| Hussain, A | 1 |
| Faiyazuddin, MD | 1 |
| Rao, CV | 1 |
| Miyazawa, N | 3 |
| Horita, N | 3 |
| Tomaru, K | 1 |
| Tsukahara, T | 1 |
| Takahashi, R | 1 |
| Sasaki, M | 1 |
| Ishigatsubo, Y | 2 |
| Jaswal, A | 1 |
| Sinha, N | 1 |
| Bhadauria, M | 1 |
| Shrivastava, S | 1 |
| Shukla, S | 1 |
| Nomi, F | 1 |
| Hosaka, K | 1 |
| Kurosawa, T | 1 |
| Satyaraddi, A | 1 |
| Velpandian, T | 1 |
| Sharma, SK | 4 |
| Vishnubhatla, S | 1 |
| Sharma, A | 2 |
| Sirohiwal, A | 1 |
| Makharia, GK | 1 |
| Sinha, S | 1 |
| Biswas, A | 1 |
| Singh, S | 2 |
| Xiang, Y | 1 |
| Ma, L | 1 |
| Wu, W | 1 |
| Liu, W | 1 |
| Li, Y | 1 |
| Zhu, X | 1 |
| Ma, J | 1 |
| Cao, M | 1 |
| Yao, X | 1 |
| Yang, L | 1 |
| Wubuli, A | 1 |
| Merle, C | 1 |
| Milligan, P | 1 |
| Mao, Y | 1 |
| Gu, J | 1 |
| Xin, X | 1 |
| Jaydeokar, AV | 1 |
| Bandawane, DD | 1 |
| Bibave, KH | 1 |
| Patil, TV | 1 |
| Teplyĭ, DL | 1 |
| Sukhanov, DS | 1 |
| Bazhanova, ED | 1 |
| Muñoz, L | 1 |
| Abubakar, I | 1 |
| Eun, JW | 1 |
| Bae, HJ | 1 |
| Shen, Q | 1 |
| Park, SJ | 1 |
| Kim, HS | 1 |
| Shin, WC | 1 |
| Yang, HD | 1 |
| Jin, CY | 1 |
| You, JS | 1 |
| Kang, HJ | 1 |
| Kim, H | 2 |
| Ahn, YM | 1 |
| Park, WS | 1 |
| Lee, JY | 1 |
| Nam, SW | 1 |
| Jeong, I | 1 |
| Park, JS | 1 |
| Cho, YJ | 1 |
| Yoon, HI | 1 |
| Lee, CT | 1 |
| Lee, JH | 1 |
| Bhushan, B | 1 |
| Chander, R | 1 |
| Kajal, NC | 1 |
| Ranga, V | 1 |
| Gupta, A | 1 |
| Bharti, H | 1 |
| Yoshiyama, T | 2 |
| Kojima, R | 1 |
| Kaneko, T | 1 |
| Dobler, CC | 1 |
| Chidiac, R | 1 |
| Williamson, JP | 1 |
| Jelfs, PJ | 1 |
| Lin, HS | 1 |
| Cheng, CW | 1 |
| Lin, MS | 1 |
| Chou, YL | 1 |
| Chang, PJ | 1 |
| Lin, JC | 1 |
| Ye, JJ | 1 |
| Zhang, Y | 3 |
| Guo, H | 1 |
| Hassan, HM | 3 |
| Ding, PP | 3 |
| Su, Y | 2 |
| Song, Y | 1 |
| Wang, T | 3 |
| Sun, L | 2 |
| Zhang, L | 2 |
| Jiang, Z | 2 |
| Pasipanodya, JG | 1 |
| Ramachandran, G | 1 |
| Shuford, S | 1 |
| Crosswell, HE | 1 |
| Cirrincione, KN | 1 |
| Sherman, CM | 1 |
| Swaminathan, S | 1 |
| Guo, HL | 2 |
| Dong, SZ | 1 |
| Sun, LX | 2 |
| Zhang, LY | 2 |
| Jiang, ZZ | 2 |
| Bright-Thomas, RJ | 1 |
| Gondker, AR | 1 |
| Morris, J | 1 |
| Ormerod, LP | 1 |
| Wang, SJ | 1 |
| Chen, X | 1 |
| Bouazzi, OE | 1 |
| Hammi, S | 1 |
| Bourkadi, JE | 1 |
| Tebaa, A | 1 |
| Tanani, DS | 1 |
| Soulaymani-Bencheikh, R | 1 |
| Badrane, N | 1 |
| Bengueddour, R | 1 |
| Adhvaryu, MR | 1 |
| Reddy, N | 1 |
| Vakharia, BC | 1 |
| Srivastava, RK | 1 |
| Verma, S | 1 |
| Arora, B | 1 |
| Lal, H | 1 |
| Akashi, I | 1 |
| Kagami, K | 1 |
| Hirano, T | 1 |
| Oka, K | 1 |
| Camacho, A | 1 |
| Pérez-Camacho, I | 1 |
| Rivero, A | 1 |
| Natera, C | 1 |
| García-Lázaro, M | 1 |
| Castón, JJ | 1 |
| Gallo, M | 1 |
| Kindelán, JM | 1 |
| Torre-Cisneros, J | 1 |
| Singla, R | 1 |
| Sarda, P | 1 |
| Mohan, A | 2 |
| Makharia, G | 1 |
| Jayaswal, A | 1 |
| Sreenivas, V | 1 |
| Lee, SW | 1 |
| Chung, LS | 1 |
| Huang, HH | 1 |
| Chuang, TY | 1 |
| Liou, YH | 1 |
| Wu, LS | 1 |
| Tostmann, A | 3 |
| Aarnoutse, RE | 3 |
| Peters, WH | 2 |
| Richard, PN | 1 |
| Boeree, MJ | 3 |
| Baniasadi, S | 1 |
| Eftekhari, P | 1 |
| Tabarsi, P | 1 |
| Fahimi, F | 1 |
| Raoufy, MR | 1 |
| Masjedi, MR | 1 |
| Velayati, AA | 1 |
| Chang, KC | 2 |
| Leung, CC | 4 |
| Rieder, HL | 1 |
| Lange, C | 1 |
| Yew, WW | 4 |
| Gulati, K | 1 |
| Ray, A | 1 |
| Vijayan, VK | 1 |
| Ikegame, S | 1 |
| Wakamatsu, K | 1 |
| Fujita, M | 1 |
| Nakanishi, Y | 1 |
| Kajiki, A | 1 |
| Colucci, G | 1 |
| Silzle, T | 1 |
| Solenthaler, M | 1 |
| Leiro-Fernandez, V | 1 |
| Valverde, D | 2 |
| Vázquez-Gallardo, R | 1 |
| Botana-Rial, M | 1 |
| Constenla, L | 2 |
| Agúndez, JA | 1 |
| Fernández-Villar, A | 2 |
| Singh, M | 1 |
| Sasi, P | 1 |
| Gupta, VH | 1 |
| Rai, G | 1 |
| Amarapurkar, DN | 1 |
| Wangikar, PP | 1 |
| Li, F | 1 |
| Zhang, S | 1 |
| Babalık, A | 1 |
| Arda, H | 1 |
| Bakırcı, N | 1 |
| Ağca, S | 1 |
| Oruç, K | 1 |
| Kızıltaş, S | 1 |
| Cetintaş, G | 1 |
| Calışır, HC | 1 |
| Shih, TY | 1 |
| Pai, CY | 1 |
| Yang, P | 1 |
| Chang, WL | 1 |
| Wang, NC | 1 |
| Hu, OY | 1 |
| Teleman, MD | 1 |
| Chee, CB | 1 |
| Earnest, A | 1 |
| Wang, YT | 1 |
| Ohkawa, K | 1 |
| Hashiguchi, M | 1 |
| Ohno, K | 1 |
| Kiuchi, C | 1 |
| Takahashi, S | 1 |
| Kondo, S | 1 |
| Echizen, H | 1 |
| Ogata, H | 2 |
| Jasmer, RM | 3 |
| Saukkonen, JJ | 1 |
| Blumberg, HM | 1 |
| Daley, CL | 2 |
| Bernardo, J | 1 |
| Vittinghoff, E | 1 |
| King, MD | 1 |
| Kawamura, LM | 1 |
| Hopewell, PC | 1 |
| Stout, JE | 1 |
| Engemann, JJ | 1 |
| Cheng, AC | 1 |
| Fortenberry, ER | 1 |
| Hamilton, CD | 1 |
| Lee, AM | 1 |
| Mennone, JZ | 1 |
| Jones, RC | 1 |
| Paul, WS | 1 |
| McNeill, L | 1 |
| Allen, M | 1 |
| Estrada, C | 1 |
| Cook, P | 1 |
| Yee, D | 1 |
| Valiquette, C | 1 |
| Pelletier, M | 1 |
| Parisien, I | 1 |
| Rocher, I | 1 |
| Menzies, D | 1 |
| Marks, SM | 1 |
| Ijaz, K | 4 |
| Iademarco, MF | 3 |
| Kunimoto, D | 1 |
| Warman, A | 1 |
| Beckon, A | 1 |
| Doering, D | 1 |
| Melenka, L | 1 |
| BEK, E | 2 |
| COTTIN, S | 1 |
| COZAN, R | 1 |
| VERAN, P | 1 |
| SERI, I | 1 |
| KOLUMBAN, K | 1 |
| BALOGH, Z | 1 |
| VULLIEMOZ, P | 1 |
| FAVEZ, G | 1 |
| BARRAS, G | 1 |
| Pandey, R | 1 |
| Zahoor, A | 1 |
| Khuller, GK | 1 |
| Prasad, B | 1 |
| Kandula, NR | 1 |
| Dworkin, MS | 1 |
| Carroll, MR | 1 |
| Lauderdale, DS | 1 |
| Marra, F | 1 |
| Cox, VC | 1 |
| FitzGerald, JM | 1 |
| Moadebi, S | 1 |
| Elwood, RK | 1 |
| McElroy, PD | 3 |
| Navin, TR | 3 |
| van Hest, R | 1 |
| Baars, H | 1 |
| Kik, S | 1 |
| van Gerven, P | 1 |
| Trompenaars, MC | 1 |
| Kalisvaart, N | 1 |
| Keizer, S | 1 |
| Borgdorff, M | 1 |
| Mensen, M | 1 |
| Cobelens, F | 1 |
| Gordin, FM | 1 |
| Cohn, DL | 1 |
| Matts, JP | 1 |
| Chaisson, RE | 1 |
| O'Brien, RJ | 2 |
| Potolidis, E | 1 |
| Mantadakis, E | 1 |
| Zeniodi, MH | 1 |
| Samonis, G | 1 |
| Lobato, MN | 1 |
| Reves, RR | 2 |
| Grabau, JC | 1 |
| Bock, NN | 1 |
| Shang, N | 1 |
| Lee, BH | 1 |
| Koh, WJ | 1 |
| Choi, MS | 1 |
| Suh, GY | 1 |
| Chung, MP | 1 |
| Kwon, OJ | 1 |
| Tasduq, SA | 2 |
| Kaisar, P | 1 |
| Gupta, DK | 2 |
| Kapahi, BK | 1 |
| Maheshwari, HS | 1 |
| Jyotsna, S | 1 |
| Johri, RK | 2 |
| Younossian, AB | 1 |
| Rochat, T | 1 |
| Ketterer, JP | 1 |
| Wacker, J | 1 |
| Janssens, JP | 1 |
| Lambert, LA | 2 |
| Jereb, JA | 2 |
| Castro, KG | 2 |
| Bower, WA | 1 |
| Spradling, PR | 1 |
| Cook, PP | 2 |
| Singh, K | 1 |
| Satti, NK | 1 |
| Suri, KA | 1 |
| Maldonado, RA | 1 |
| Yarnell, CT | 1 |
| Holbert, D | 1 |
| Campos-Varela, I | 1 |
| Perich-Jackson, D | 1 |
| Ferrer-Sancho, J | 1 |
| Markov, M | 1 |
| Patel, K | 1 |
| Raeesy, A | 1 |
| Bant, A | 1 |
| Van Thiel, DH | 1 |
| Nadir, A | 1 |
| de Lange, WC | 1 |
| van der Ven, AJ | 2 |
| Dekhuijzen, R | 1 |
| P V, K | 1 |
| Palaian, S | 1 |
| Ojha, P | 1 |
| P R, S | 1 |
| Roelofs, HM | 1 |
| Dekhuijzen, PN | 1 |
| Lau, TY | 1 |
| Tam, CM | 1 |
| Panchabhai, TS | 1 |
| Ambarkhane, SV | 1 |
| Joshi, AS | 1 |
| Samant, BD | 1 |
| Rege, NN | 1 |
| Leiro, V | 1 |
| Vázquez, R | 1 |
| Piñeiro, L | 1 |
| González-Quintela, A | 1 |
| Somner, AR | 1 |
| Brace, AA | 1 |
| Phillips, S | 1 |
| Danan, G | 1 |
| Pessayre, D | 1 |
| Larrey, D | 1 |
| Benhamou, JP | 1 |
| Pretet, S | 1 |
| Perdrizet, S | 1 |
| Cataldi Amatriain, RM | 1 |
| Rossi Case, E | 1 |
| Fiala, W | 1 |
| Häcki, MA | 1 |
| Brändli, O | 2 |
| Zierski, M | 2 |
| Lefrock, JL | 1 |
| Smith, BR | 1 |
| Cohen, CD | 1 |
| Sayed, AR | 1 |
| Kirsch, RE | 1 |
| Sbarbaro, JA | 1 |
| Estay, S | 1 |
| Armas Merino, R | 1 |
| Vega, C | 1 |
| Soto, JR | 1 |
| Urban, T | 1 |
| Maquarre, E | 1 |
| Housset, C | 1 |
| Chouaid, C | 1 |
| Devin, E | 1 |
| Lebeau, B | 1 |
| Singh, J | 2 |
| Arora, A | 1 |
| Garg, PK | 2 |
| Thakur, VS | 2 |
| Pande, JN | 1 |
| Tandon, RK | 2 |
| Corbella, X | 1 |
| Vadillo, M | 1 |
| Cabellos, C | 1 |
| Fernandez-Viladrich, P | 1 |
| Rufi, G | 1 |
| van der Kooi, K | 1 |
| Mottet, JJ | 1 |
| Regamey, C | 1 |
| Padmini, R | 1 |
| Srinivasan, S | 1 |
| Nalini, P | 1 |
| Mahadevan, S | 1 |
| Türktaş, H | 1 |
| Unsal, M | 1 |
| Tülek, N | 1 |
| Orüç, O | 1 |
| Robson, SC | 1 |
| Pillans, P | 1 |
| Willcox, PA | 1 |
| Altman, C | 1 |
| Biour, M | 1 |
| Grangé, JD | 1 |
| Ali, J | 1 |
| Døssing, M | 1 |
| Wilcke, JT | 1 |
| Askgaard, DS | 1 |
| Nybo, B | 1 |
| Moitinho, E | 1 |
| Salmerón, JM | 1 |
| Mas, A | 1 |
| Bruguera, M | 1 |
| Rodés, J | 1 |
| Ridzon, R | 1 |
| Meador, J | 1 |
| Maxwell, R | 1 |
| Higgins, K | 1 |
| Weismuller, P | 1 |
| Onorato, IM | 1 |
| Fattinger, K | 1 |
| Braunschweig, S | 1 |
| Reichen, J | 1 |
| Meier-Abt, PJ | 1 |
| Krähenbühl, S | 1 |
| Knobel, B | 1 |
| Buyanowsky, G | 1 |
| Dan, M | 1 |
| Zaidel, L | 1 |
| Devoto, FM | 1 |
| González, C | 1 |
| Iannantuono, R | 1 |
| Serra, HA | 1 |
| González, CD | 1 |
| Sáenz, C | 1 |
| Beji, M | 1 |
| Louzir, B | 1 |
| Ben Rhomdane, N | 1 |
| Zouari, M | 1 |
| Mtimet, B | 1 |
| Daghfous, J | 1 |
| Mbaye, PS | 1 |
| Talarmin, F | 1 |
| Sane, M | 1 |
| Eladari, D | 1 |
| Klotz, F | 1 |
| Rose, DN | 1 |
| Corrigan, D | 1 |
| Paton, J | 1 |
| Wada, M | 3 |
| Ito, K | 1 |
| Mizutani, S | 1 |
| Sugita, H | 1 |
| Gusmão Filho, FA | 1 |
| Marques-Dias, MJ | 1 |
| Marques, HH | 1 |
| Ramos, SR | 1 |
| McCarthy, M | 1 |
| Vu, D | 1 |
| Macdonald, L | 1 |
| Burman, WJ | 1 |
| de Maria, A | 1 |
| Berardi, M | 1 |
| Dignetti, P | 1 |
| Ferrera, L | 1 |
| Viassolo, L | 1 |
| Canonica, GW | 1 |
| Gned'ko, NI | 1 |
| Newton, RW | 1 |
| Rossouw, JE | 1 |
| Saunders, SJ | 1 |
| Girling, DJ | 1 |
| Lee, J | 1 |
| Wong, PC | 1 |
| Kwan, SY | 1 |
| Skakun, NP | 1 |
| Slivka, IuI | 3 |
| Neill, P | 1 |
| Pringle, D | 1 |
| Mhonda, M | 1 |
| Kusema, T | 1 |
| Nhachi, CF | 1 |
| Musch, E | 1 |
| Loos, U | 1 |
| Schwabe, HK | 1 |
| Roden, S | 1 |
| Lagneau, M | 1 |
| Homasson, JP | 1 |
| Klimniuk, EV | 1 |
| Tabachuk, OE | 1 |
| Donald, PR | 1 |
| Schoeman, JF | 1 |
| O'Kennedy, A | 1 |
| Goldberger, MJ | 1 |
| van Aalderen, WM | 1 |
| Knoester, H | 1 |
| Knol, K | 1 |
| Parthasarathy, R | 1 |
| Sarma, GR | 1 |
| Janardhanam, B | 1 |
| Ramachandran, P | 1 |
| Santha, T | 1 |
| Sivasubramanian, S | 1 |
| Somasundaram, PR | 1 |
| Tripathy, SP | 1 |
| Mukerjee, CM | 1 |
| McKenzie, DK | 1 |
| Karrer, W | 1 |
| Röthlisberger, K | 1 |
| Bezel, R | 1 |
| Häcki, M | 1 |
| Rubin, S | 1 |
| Vil'derman, AM | 1 |
| Horsfall, PA | 1 |
| Beckert, W | 3 |
| Lester, W | 1 |
| Rabina, EV | 1 |
| Semichastnova, AG | 1 |
| Golubiatnikova, GA | 1 |
| Wolinsky, E | 1 |
| Dölle, W | 1 |
| Radecki, A | 1 |
| Kanwiszer, H | 1 |
| Krzanowska, E | 1 |
| Donderowicz, A | 1 |
| Bignall, JR | 1 |
| Lind, A | 1 |
| Rist, N | 1 |
| Matzel, W | 1 |
| Lindemann, I | 1 |
| Simpson, AJ | 1 |
| Mirza, AM | 1 |
| Martin, JF | 1 |
| O'Brien, TF | 1 |
| Grymiński, J | 1 |
| Lyczewska, J | 1 |
| Styszewska, H | 1 |
| Walczak, J | 1 |
| Zítková, L | 3 |
| Stastná, J | 3 |
| Celikovská, G | 3 |
| Kürti, V | 2 |
| Viklický, J | 1 |
| Brezinová, H | 1 |
| Kropp, R | 1 |
| Hess, W | 1 |
| Jungbluth, H | 1 |
| Pickroth, G | 1 |
| Uehlinger, E | 1 |
| Petera, V | 1 |
| Klapálek, D | 1 |
| Paichl, P | 1 |
| Pecený, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy[NCT03982277] | Phase 2 | 130 participants (Actual) | Interventional | 2019-04-30 | Completed | ||
| Estimation of Plasma Free and Total Drug Levels of Rifampicin, Isoniazid and Pyrazinamide in Patients on Antituberculosis Therapy and Its Correlation With Development of Drug Induced Hepatotoxicity[NCT01456845] | 110 participants (Actual) | Observational | 2010-08-31 | Completed | |||
| Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Antituberculosis Treatment Induced Hepatotoxicity[NCT00405301] | Phase 4 | 175 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| A Randomized Double Blind Placebo Controlled Trial of Adjunctive Dexamethasone for the Treatment of HIV-infected Adults With Tuberculous Meningitis[NCT03092817] | Phase 3 | 520 participants (Actual) | Interventional | 2017-05-25 | Active, not recruiting | ||
| A Randomized Double Blind Placebo Controlled Non-inferiority Trial of Adjunctive Dexamethasone for the Treatment of HIV-uninfected Adults With Tuberculous Meningitis Stratified by Leukotriene A4 Hydrolase Genotype[NCT03100786] | Phase 3 | 640 participants (Anticipated) | Interventional | 2018-02-08 | Recruiting | ||
| Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment[NCT01724723] | Phase 4 | 50 participants (Anticipated) | Interventional | 2012-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17 reviews available for pyrazinamide and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
Antitubercular drugs induced liver injury: an updated insight into molecular mechanisms.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injur | 2023 |
Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Liver; Pyrazinamide; Tubercul | 2021 |
Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Drug Combinations; Huma | 2017 |
Treatment of latent tuberculosis infection: a network meta-analysis.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Th | 2014 |
[Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials].
Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Antitubercular Agents; Chemical and Drug Induced Liver Inju | 2010 |
Treatment of latent infection with Mycobacterium tuberculosis: update 2010.
Topics: Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Communicable Disease Control; Drug | 2011 |
Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Cos | 2003 |
Antituberculosis drugs and hepatotoxicity.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Dru | 2006 |
Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Humans; In | 2008 |
[Toxicity of pyrazinamide in antituberculous treatments (author's transl)].
Topics: Chemical and Drug Induced Liver Injury; Diarrhea; Drug Eruptions; Gout; Humans; Isoniazid; Nausea; P | 1980 |
[Pharmacology, toxicology and clinical use of pyrazinamide (author's transl)].
Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; H | 1981 |
Tuberculosis.
Topics: Alcohol Drinking; Carrier State; Chemical and Drug Induced Liver Injury; Ethambutol; Humans; Isoniaz | 1980 |
[Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; E | 2001 |
Antitubercular drugs (isoniazid, rifampin and pyrazinamide): hepatobiliary reactions.
Topics: Antitubercular Agents; Biliary Tract Diseases; Chemical and Drug Induced Liver Injury; Humans; Isoni | 2001 |
The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.
Topics: Acetylation; Adolescent; Adult; Aged; Chemical and Drug Induced Liver Injury; Clinical Trials as Top | 1978 |
Antituberculosis agents.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ethambutol | 1988 |
15 trials available for pyrazinamide and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Association of UGT2B7 polymorphisms with risk of induced liver injury by anti-tuberculosis drugs in Chinese Han.
Topics: Adult; Antitubercular Agents; Asian People; Chemical and Drug Induced Liver Injury; Drug Therapy, Co | 2017 |
Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study.
Topics: Age Factors; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug | 2019 |
Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach.
Topics: Adult; Antitubercular Agents; Blood Sedimentation; Body Weight; Chemical and Drug Induced Liver Inju | 2008 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver Inju | 2010 |
Assessment of protective role of polyherbal preparation, Livina, against anti-tubercular drug induced liver dysfunction.
Topics: Adolescent; Adult; Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferases; Chemica | 2010 |
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induced Liver Injury; D | 2002 |
[Pyrazinamide versus ethambutol in short-term therapy of lung tuberculosis. A randomized study].
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ethambutol; Humans; | 1983 |
Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clinical Tri | 1980 |
Antituberculosis treatment-induced hepatotoxicity: role of predictive factors.
Topics: Adolescent; Adult; Antitubercular Agents; Body Mass Index; Case-Control Studies; Chemical and Drug I | 1995 |
Hepatic enzyme abnormalities in children on triple therapy for tuberculosis.
Topics: Adolescent; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; | 1999 |
The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.
Topics: Acetylation; Adolescent; Adult; Aged; Chemical and Drug Induced Liver Injury; Clinical Trials as Top | 1978 |
A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore.
Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as | 1986 |
[Which is the best drug combination for the short-term therapy of tuberculosis? A prospective randomized study with 190 patients].
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug | 1985 |
[Toxic reactions during treament with pyrazinamide in pulmonary tuberculosis].
Topics: Adult; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Female; Humans; Male; Middl | 1968 |
173 other studies available for pyrazinamide and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
The role of the farnesoid X receptor in quadruple anti-tuberculosis drug-induced liver injury.
Topics: Animals; Antitubercular Agents; Bile Acids and Salts; Chemical and Drug Induced Liver Injury; Chemic | 2022 |
Pyrazinamide related prolonged drug-induced liver injury: A case report.
Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced Liver Injury; Ethamb | 2022 |
Molecular and cellular remodeling of HepG2 cells upon treatment with antitubercular drugs.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Hep G2 Cells; Humans; Isoniazid; Pyra | 2023 |
Near-infrared molecular sensor for visualizing and tracking ONOO
Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Fluorescent Dyes; HeLa Cells | 2023 |
Association of ABCC Gene Polymorphism With Susceptibility to Antituberculosis Drug-Induced Hepatotoxicity in Western Han Patients With Tuberculosis.
Topics: Adult; Alanine Transaminase; Antitubercular Agents; Asian People; ATP-Binding Cassette Transporters; | 2020 |
Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Isoniazid; Mal | 2020 |
Bile acids, lipid and purine metabolism involved in hepatotoxicity of first-line anti-tuberculosis drugs.
Topics: Animals; Antitubercular Agents; Bile Acids and Salts; Chemical and Drug Induced Liver Injury; Chroma | 2020 |
An Evaluation of the In Vitro Roles and Mechanisms of Silibinin in Reducing Pyrazinamide- and Isoniazid-Induced Hepatocellular Damage.
Topics: Antitubercular Agents; Apoptosis; Cell Line; Chemical and Drug Induced Liver Injury; Hepatocytes; Hu | 2020 |
Evidence of drug-induced hepatotoxicity in the Maghrebian population.
Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug-Related Side | 2022 |
Clinical characteristics of pyrazinamide-associated hepatotoxicity in patients at a hospital in Lima, Peru.
Topics: Adult; Chemical and Drug Induced Liver Injury; Hospitals; Humans; Peru; Pyrazinamide; Tuberculosis | 2020 |
Ameliorative potential of Adhatoda vasica against anti-tubercular drugs induced hepatic impairments in female Wistar rats in relation to oxidative stress and xeno-metabolism.
Topics: Alkaloids; Animals; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced | 2021 |
Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population.
Topics: Adult; Alleles; Antitubercular Agents; Asian People; Chemical and Drug Induced Liver Injury; Cytochr | 2017 |
Metabolomics approach discriminates toxicity index of pyrazinamide and its metabolic products, pyrazinoic acid and 5-hydroxy pyrazinoic acid.
Topics: Administration, Oral; Animals; Antitubercular Agents; Biomarkers; Biotransformation; Chemical and Dr | 2018 |
First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Chromatography, High Pressure | 2018 |
Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Hum | 2018 |
Evaluation of antihepatotoxic potential of Solanum xanthocarpum fruit extract against antitubercular drugs induced hepatopathy in experimental rodents.
Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Fema | 2012 |
[Comparison of drug-induced hepatitis occurring in elderly and younger patients during anti-tuberculosis treatment with a regimen including pyrazinamide].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug In | 2013 |
Therapeutic potential of thymoquinone against anti-tuberculosis drugs induced liver damage.
Topics: Analysis of Variance; Animals; Antitubercular Agents; Benzoquinones; Blood Chemical Analysis; Chemic | 2013 |
[A clinical investigation of seven patients with pulmonary tuberculosis who developed mixed liver injury during oral anti-tuberculosis treatment].
Topics: Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2013 |
Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity.
Topics: Adult; Antitubercular Agents; Area Under Curve; Case-Control Studies; Chemical and Drug Induced Live | 2014 |
Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity.
Topics: Adult; Antitubercular Agents; Area Under Curve; Case-Control Studies; Chemical and Drug Induced Live | 2014 |
Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity.
Topics: Adult; Antitubercular Agents; Area Under Curve; Case-Control Studies; Chemical and Drug Induced Live | 2014 |
Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity.
Topics: Adult; Antitubercular Agents; Area Under Curve; Case-Control Studies; Chemical and Drug Induced Live | 2014 |
The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced Liver Injury; | 2014 |
Hepatoprotective potential of Cassia auriculata roots on ethanol and antitubercular drug-induced hepatotoxicity in experimental models.
Topics: Animals; Antioxidants; Antitubercular Agents; Cassia; Chemical and Drug Induced Liver Injury; Diseas | 2014 |
[Mechanism of hepatocyte apoptosis in experimental toxic liver injury].
Topics: Animals; Apoptosis; Caspase 3; Caspase 8; Chemical and Drug Induced Liver Injury; fas Receptor; Gene | 2013 |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
Topics: Animals; Biomarkers; Carbamazepine; Chemical and Drug Induced Liver Injury; Chlorpromazine; Disease | 2015 |
Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antitubercular Agents; Aspartate A | 2015 |
Profile of adverse drug reactions in drug resistant tuberculosis from Punjab.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Arthralgia; Ataxia; Chemical and Drug Induced Liver | 2014 |
Currently Used Low-Dose Pyrazinamide Does Not Increase Liver-Injury in the First Two Months of Tuberculosis Treatment.
Topics: Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Dru | 2015 |
[DRUG-INDUCED LIVER INJURY AND PYRAZINAMIDE USE].
Topics: Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Male; Pyrazinam | 2015 |
Repeat exposure to active tuberculosis and risk of re-infection.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Emergency Service, Hospital; E | 2016 |
The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver I | 2016 |
Pyrazinamide induced hepatic injury in rats through inhibiting the PPARα pathway.
Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Down-Regulation; Female; Fen | 2016 |
A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies.
Topics: Acetaminophen; Antitubercular Agents; Cell Line; Chemical and Drug Induced Liver Injury; Child, Pres | 2016 |
Pyrazinamide Induced Rat Cholestatic Liver Injury through Inhibition of FXR Regulatory Effect on Bile Acid Synthesis and Transport.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blotting, Western; Chemical and Drug Ind | 2016 |
Association between TXNRD1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a prospective study.
Topics: Adult; Age Factors; Alleles; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Ethambut | 2016 |
Drug-related hepatitis in patients treated with standard anti-tuberculosis chemotherapy over a 30-year period.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver I | 2016 |
Pyrazinamide-induced hepatotoxicity is alleviated by 4-PBA via inhibition of the PERK-eIF2α-ATF4-CHOP pathway.
Topics: Activating Transcription Factor 4; Alanine Transaminase; Animals; Apoptosis; Aspartate Aminotransfer | 2017 |
First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.
Topics: Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Monitoring; Female; | 2016 |
Influence of diabetes on liver injury induced by antitubercular drugs and on silymarin hepatoprotection in rats.
Topics: Animals; Antitubercular Agents; Bilirubin; Chemical and Drug Induced Liver Injury; Diabetes Mellitus | 2008 |
Protective effects of coffee-derived compounds on lipopolysaccharide/D-galactosamine induced acute liver injury in rats.
Topics: Alanine Transaminase; Alkaloids; Animals; Aspartate Aminotransferases; Caffeine; Chemical and Drug I | 2009 |
NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and D | 2010 |
Xanthine oxidase inhibition by allopurinol increases in vitro pyrazinamide-induced hepatotoxicity in HepG2 cells.
Topics: Allopurinol; Antitubercular Agents; Area Under Curve; Cell Survival; Chemical and Drug Induced Liver | 2010 |
The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Pyrazinamide; Rifa | 2010 |
A case of isoniazid-induced liver injury diagnosed by use of the DLST, and successful reintroduction of isoniazid for pleural tuberculosis.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Desensitization, Immunologic; Ethambu | 2011 |
Pyrazinamide-induced sideroblastic anemia.
Topics: 5-Aminolevulinate Synthetase; alpha-Thalassemia; Anemia, Sideroblastic; Antitubercular Agents; Aza C | 2012 |
N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Case-Control Studies; Chemical and Drug | 2011 |
Protective effect of curcumin, silymarin and N-acetylcysteine on antitubercular drug-induced hepatotoxicity assessed in an in vitro model.
Topics: Acetylcysteine; Antitubercular Agents; Cell Cycle; Cell Survival; Chemical and Drug Induced Liver In | 2012 |
Gene expression profiling reveals potential key pathways involved in pyrazinamide-mediated hepatotoxicity in Wistar rats.
Topics: Animals; Antioxidants; Apoptosis; Chemical and Drug Induced Liver Injury; Dose-Response Relationship | 2013 |
Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
Topics: Adult; Age Factors; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Comorbidity; Drug | 2012 |
A novel mechanism underlies the hepatotoxicity of pyrazinamide.
Topics: Alanine Transaminase; Animals; Antitubercular Agents; Aspartate Aminotransferases; Cell Survival; Ch | 2013 |
Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore.
Topics: Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferases; Bilirubin; Chemical and Dr | 2002 |
Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.
Topics: Adolescent; Analysis of Variance; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Chi | 2002 |
Summaries for patients. Short-course treatment for latent tuberculosis is associated with more frequent liver injury than long-course treatment is.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induced Liver Injury; D | 2002 |
Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.
Topics: Adolescent; Adult; Aged; Alcoholism; Antibiotics, Antitubercular; Antitubercular Agents; Chemical an | 2003 |
Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Humans; Pr | 2002 |
Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Anti-Bacterial Agents; Antib | 2002 |
From the Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Humans; Pr | 2002 |
Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induc | 2003 |
Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug In | 2003 |
Management of latent tuberculosis infection in immigrants.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cost-Benefit Analysis; Drug Resistanc | 2003 |
Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Centers for Disease Control and Preventio | 2003 |
Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Humans; Py | 2003 |
[INTOLERANCE AND TOXICITY OF SUBSTITUTE ANTIBACTERIAL DRUGS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Chemical and Drug Induced Liver In | 1963 |
[APROPOS OF ETHIONAMIDE JAUNDICE].
Topics: Alanine Transaminase; Alcoholism; Aminosalicylic Acid; Aminosalicylic Acids; Aspartate Aminotransfer | 1964 |
[EFFECT OF PYRAZINAMIDE ON INACTIVE DUODENAL ULCER].
Topics: Chemical and Drug Induced Liver Injury; Drug Therapy; Duodenal Ulcer; Hepatitis; Liver Function Test | 1964 |
[ENZYMATIC STUDY OF THE LIVER IN PULMONARY TUBERCULOSIS. RESEARCH ON A POSSIBLE HEPATOTOXIC EFFECT OF ANTIBACTERIAL MEDICATIONS].
Topics: Alanine Transaminase; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Aspartate Am | 1964 |
REACTIONS TO ANTITUBERCULOSIS DRUGS AMONG CHINESE IN HONG KONG.
Topics: Alcoholism; Alopecia; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Asian People | 1964 |
[STUDY ON LIVER TOLERANCE TO N-(4-MORPHOLINOMETHYL-PYRAZINAMIDE) IN THE TREATMENT OF PULMONARY TUBERCULOSIS].
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Tolerance; Hepatitis; Humans; Py | 1964 |
USPHS-CDC news.
Topics: Centers for Disease Control and Prevention, U.S.; Chemical and Drug Induced Liver Injury; Communicat | 2003 |
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Topics: Administration, Inhalation; Aerosols; Animals; Antibiotics, Antitubercular; Antitubercular Agents; A | 2003 |
Tuberculosis prevention in Mexican immigrants: limitations of short-course therapy.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Chemical and Drug Induced Liver Injury; Child; Child | 2004 |
Side effects of antituberculosis drugs.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Pyrazinamide | 2004 |
Antituberculosis drugs and hepatotoxicity.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Humans; Is | 2004 |
Successful treatment of multidrug-resistant tuberculosis following drug-induced hepatic necrosis requiring liver transplant.
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Ciprofl | 2004 |
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Liver Diseases; Pyrazinamide; | 2004 |
Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotics, Antitubercular; Chemical and Drug Induced Liv | 2004 |
Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
Topics: Adolescent; Adult; Aspartate Aminotransferases; Bilirubin; Chemical and Drug Induced Liver Injury; D | 2004 |
Rifampin plus pyrazinamide-induced hepatitis requiring hospitalization in a 30-y-old male with latent tuberculosis.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Human | 2005 |
Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cohort Studi | 2005 |
Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Topics: Adult; Antitubercular Agents; Carrier State; Case-Control Studies; Chemical and Drug Induced Liver I | 2005 |
Protective effect of a 50% hydroalcoholic fruit extract of Emblica officinalis against anti-tuberculosis drugs induced liver toxicity.
Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Fruit; Hepatocytes; Humans; | 2005 |
High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis.
Topics: Adult; Antitubercular Agents; Carrier State; Chemical and Drug Induced Liver Injury; Dose-Response R | 2005 |
National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Health Surveys; Hospitalization; Huma | 2005 |
Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Antitubercular Agents; Chemical and Drug Induced Liver In | 2006 |
Rifampin and pyrazinamide for treatment of latent tuberculosis infection.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Hospitalization; Humans; Liver Diseas | 2006 |
Terminalia chebula (fruit) prevents liver toxicity caused by sub-chronic administration of rifampicin, isoniazid and pyrazinamide in combination.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Cell Survival; Cells, Cultured; Chemica | 2006 |
Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Male; Patient | 2006 |
[Addisonian crises induced by rifampicin].
Topics: Addison Disease; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Female; Humans | 2006 |
Liver and pancreatic injury induced by antituberculous therapy.
Topics: Adult; Antitubercular Agents; Biopsy; Chemical and Drug Induced Liver Injury; Cholangiopancreatograp | 2007 |
Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antitubercular Agents; Aspa | 2008 |
Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity.
Topics: Antitubercular Agents; Cell Line, Tumor; Cell Survival; Chemical and Drug Induced Liver Injury; Huma | 2008 |
Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
Topics: Adult; Aged; Antitubercular Agents; Case-Control Studies; Chemical and Drug Induced Liver Injury; Dr | 2008 |
Protective effect of Tinospora cordifolia, Phyllanthus emblica and their combination against antitubercular drugs induced hepatic damage: an experimental study.
Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; I | 2008 |
Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population.
Topics: Adult; Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferases; Case-Control Studie | 2008 |
Changes in serum transaminase due to prothionamide.
Topics: Adult; Chemical and Drug Induced Liver Injury; Drug Resistance, Microbial; Ethionamide; Female; Huma | 1967 |
Pyrazinamide-isoniazid: its apparent influence on the reactivation rate in pulmonary tuberculosis.
Topics: Adult; Aminosalicylic Acids; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Middle Aged; | 1967 |
Pyrazinamide fulminant hepatitis: an old hepatotoxin strikes again.
Topics: Adult; Chemical and Drug Induced Liver Injury; Humans; Male; Pyrazinamide; Tuberculosis, Pulmonary | 1981 |
[The hepatotoxicity of pyrazinamide].
Topics: Chemical and Drug Induced Liver Injury; Humans; Kinetics; Male; Pyrazinamide; Tuberculosis, Pulmonar | 1984 |
Tuberculosis therapy.
Topics: Chemical and Drug Induced Liver Injury; Drug Resistance, Microbial; Drug Therapy, Combination; Human | 1983 |
Hepatic complications of antituberculosis therapy revisited.
Topics: Adolescent; Adult; Aged; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Drug Thera | 1983 |
[Clinically apparent liver damage during brief tuberculosis therapy].
Topics: Acute Disease; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, C | 1981 |
[Allopurinol hypersensitivity. A possible cause of hepatitis and mucocutaneous eruptions in a patient undergoing antitubercular treatment].
Topics: Adult; Allopurinol; Chemical and Drug Induced Liver Injury; Drug Eruptions; Drug Hypersensitivity; D | 1995 |
Anti tubercular treatment induced hepatotoxicity: does acetylator status matter?
Topics: Acetylation; Adult; Antitubercular Agents; Biomarkers; Chemical and Drug Induced Liver Injury; Drug | 1995 |
Hypersensitivity hepatitis due to pyrazinamide.
Topics: Acute Disease; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Drug Hypers | 1995 |
Isoniazid is not always the cause of hepatitis during treatment of tuberculosis.
Topics: Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Male; Middle Aged; Pyrazinamide; Tubercul | 1994 |
Short course chemotherapy for tuberculosis in children.
Topics: Adolescent; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Dose-Response Relations | 1993 |
Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis.
Topics: Acute Disease; Adolescent; Adult; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; D | 1994 |
Treatment of tuberculosis in patients with pre-existing liver disease or following hepatotoxic drug reactions.
Topics: Chemical and Drug Induced Liver Injury; Clinical Protocols; Contraindications; Humans; Isoniazid; Li | 1993 |
[Hepatic toxicity of antitubercular agents. Role of different drugs. 199 cases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Child; Child, Pr | 1993 |
Hepatotoxic effects of tuberculosis therapy. A practical approach to a tricky management problem.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; | 1996 |
Liver injury during antituberculosis treatment: an 11-year study.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Antitubercular Agents; Aspartate Aminotransferases; Bilir | 1996 |
[Severe hepatotoxicity of tuberculostatic agents. Increase in the incidence].
Topics: Acute Disease; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induced | 1996 |
Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin.
Topics: Adolescent; Adult; Alanine Transaminase; Antitubercular Agents; Chemical and Drug Induced Liver Inju | 1997 |
[Liver injury under tuberculostatic treatment].
Topics: Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Combinations; Female; Huma | 1997 |
Pyrazinamide-induced granulomatous hepatitis.
Topics: Antitubercular Agents; Biopsy; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Gr | 1997 |
[First-time standard setting for therapy of pulmonary tuberculosis after revision of the Medical Treatment Standard--special reference to results of questionnaire survey on reality of early stage short-term PZA therapy and occurrence of the adverse effect
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy; Gout; Humans; Japan; Li | 1997 |
Risk factors for hepatotoxicity induced by antituberculosis drugs.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Etham | 1997 |
[Thrombocytopenia following a re-introduction of rifampicin in a daily treatment. Apropos of a case].
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induced Liver Injury; D | 1995 |
[Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Th | 1995 |
Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis.
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Chemical | 1998 |
[Six-months chemotherapy (2HRZS or E/4HRE) of new cases of pulmonary tuberculosis--six year experiences on its effectiveness, toxicity, and acceptability].
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Diabetes Complications; Drug T | 1999 |
[The effectiveness of pyrazinamide-containing six-month short course chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Diabe | 2000 |
[Central nervous system tuberculosis in children: 2. Treatment and outcome].
Topics: Adolescent; Adrenal Cortex Hormones; Antitubercular Agents; Chemical and Drug Induced Liver Injury; | 2001 |
Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Fatal Outc | 2001 |
Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Fatal Outcome; Female; Georgia; Human | 2001 |
US guidelines for treatment of latent tuberculosis revised.
Topics: Chemical and Drug Induced Liver Injury; Drug Combinations; Humans; Practice Guidelines as Topic; Pyr | 2001 |
From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
Topics: Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combinatio | 2001 |
Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers.
Topics: Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Chemical and Drug Induced L | 2001 |
Side effects of antituberculosis treatment.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, | 2001 |
Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
Topics: Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combinatio | 2001 |
[Medication-induced hepatic lesions in patients with pulmonary tuberculosis].
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Ethionamide; Humans; Pyrazinamide; Ri | 2002 |
Side effects of drugs used to treat tuberculosis.
Topics: Aminosalicylic Acids; Animals; Antitubercular Agents; Capreomycin; Chemical and Drug Induced Liver I | 1975 |
Hepatic complications of antituberculous therapy.
Topics: Aminosalicylic Acids; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Hypersensi | 1975 |
Adverse reactions to short-course regimens containing streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong.
Topics: Aminosalicylic Acids; Arthritis; Chemical and Drug Induced Liver Injury; Drug Eruptions; Drug Therap | 1976 |
Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Drug Monitoring; Drug Therap | 1992 |
[Effectiveness of tocopherol and anti-hypoxic agents in liver damage caused by antitubercular agents].
Topics: Animals; Antioxidants; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Hepatitis, An | 1991 |
Hepatoxic reaction to antituberculous drugs: Adjustments to therapeutic regimen.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clinical Protocols; Humans; Isoniazid | 1991 |
Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population.
Topics: Alanine Transaminase; Alkaline Phosphatase; Chemical and Drug Induced Liver Injury; Drug Therapy, Co | 1990 |
[Clinico-pharmacokinetic interactions of rifampicin, pyrazinamide and isoniazide].
Topics: Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Humans; Infusions, Intravenous; I | 1990 |
[Fulminant hepatitis induced by pyrazinamide].
Topics: Aged; Chemical and Drug Induced Liver Injury; Humans; Male; Pyrazinamide; Tuberculosis, Pulmonary | 1990 |
[Hepatotoxic effect of a combination of pyrazinamide with isoniazid and rifampicin].
Topics: Animals; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Drug Synergism; I | 1989 |
Hepatic toxicity during chemotherapy for severe tuberculosis meningitis.
Topics: Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferases; Chemical and Drug Induced | 1987 |
[The hepatotoxic action of pyrazinamide and its effect on lipid peroxidation].
Topics: Animals; Bile Acids and Salts; Chemical and Drug Induced Liver Injury; Lipid Peroxidation; Liver; Ma | 1988 |
Drugs for tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Drug Administrati | 1988 |
Fulminant hepatitis during treatment with rifampicin, pyrazinamid and ethambutol.
Topics: Cervical Vertebrae; Chemical and Drug Induced Liver Injury; Child; Drug Therapy, Combination; Ethamb | 1987 |
Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide.
Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child, Pres | 1986 |
Safety of thrice-weekly rifampicin for tuberculosis in South-East Asian refugees.
Topics: Adolescent; Adult; Aged; Asia, Southeastern; Australia; Chemical and Drug Induced Liver Injury; Chil | 1985 |
[Characteristics of drug-induced hepatitis in patients with tuberculosis].
Topics: Aminosalicylic Acids; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Ethionamide; Hu | 1972 |
Treatment of resistant pulmonary tuberculosis in Hong Kong with regimens of second-line drugs.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Chemical and Drug Induced Liver Injury; Cycloserine; | 1972 |
[Histological follow-up studies on drug induced liver necroses].
Topics: Aspartate Aminotransferases; Biopsy; Chemical and Drug Induced Liver Injury; Ethionamide; Follow-Up | 1973 |
Treatment of drug-resistant tuberculosis.
Topics: Aminosalicylic Acids; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cycloserine; Dr | 1971 |
[Agranulocytosis and toxic hepatic dystrophy during treatment with tuberculostatic drugs].
Topics: Aged; Agranulocytosis; Antitubercular Agents; Carcinoma, Hepatocellular; Chemical and Drug Induced L | 1972 |
New antituberculosis drugs and concepts of prophylaxis.
Topics: Aminosalicylic Acids; Antitubercular Agents; Arthritis; Chemical and Drug Induced Liver Injury; Chil | 1974 |
[Centrilobular parenchymal necrosis of the liver. A contribution to the knowledge of drug induced lesions of the liver (author's transl)].
Topics: Biopsy; Chemical and Drug Induced Liver Injury; Ethionamide; Humans; Liver; Necrosis; Pyrazinamide; | 1973 |
[Toxicity of antitubercular agents for the liver].
Topics: Aminosalicylic Acids; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cycloserine; Et | 1973 |
A comparison of regimens of ethionamide, pyrazinamide and cycloserine in re-treatment of patients with pulmonary tuberculosis.
Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Cycloserine; Ethionamide; Gastrointestina | 1969 |
[Liver toxicity of aetina and pyracinamide and their control by determination of LAP activity in blood serum].
Topics: Adult; Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferases; Chemical and Drug I | 1969 |
[Centrilobular liver necrosis following antimycobacterial treatment].
Topics: Antitubercular Agents; Biopsy; Chemical and Drug Induced Liver Injury; Ethionamide; Humans; Liver Di | 1971 |
Hepatitis secondary to pyrazinamide toxicity: accompaniments of transient hypolipoproteinemia, acanthocytosis, and changes in stomach and small bowel.
Topics: Abetalipoproteinemia; Adult; Chemical and Drug Induced Liver Injury; Erythrocytes, Abnormal; Female; | 1970 |
Evaluation of the hepatotoxic effect of antituberculous drugs in tuberculosis patients abusing alcohol.
Topics: Acute Disease; Adult; Alcoholism; Aminosalicylic Acids; Antitubercular Agents; Chemical and Drug Ind | 1970 |
[Liver damage after administration of pyrazinamide in animal experiments. I. Changes in body weight of rats under effect of pyrazinamide].
Topics: Animals; Body Weight; Chemical and Drug Induced Liver Injury; Depression, Chemical; Feeding Behavior | 1970 |
[Liver damage after administration of pyrazinamide in animal experiments. II. Studies on temporary changes of pyrazinamide concentration in blood and of activity of serum-transaminases].
Topics: Animals; Chemical and Drug Induced Liver Injury; Male; Pyrazinamide; Rats; Stimulation, Chemical; Tr | 1970 |
[Liver damage after administration of pyrazinamide in animal experiments. 3. Biochemical changes in liver tissue and blood serum].
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Chemical and Drug | 1970 |
[Studies on the liver toxicity of pyrazinamide].
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Enzymes; Humans; Male; Middle Aged; Pyrazinamid | 1968 |
[Liver damage in tuberculosis].
Topics: Bile Acids and Salts; Bilirubin; Biopsy; Chemical and Drug Induced Liver Injury; Ethionamide; Fatty | 1968 |
[Significance of liver biopsy in the scope of tuberculosis].
Topics: Adult; Biopsy; Chemical and Drug Induced Liver Injury; Humans; Male; Middle Aged; Pyrazinamide; Tube | 1969 |
[On the problem of chronic liver damage following drug therapy of tuberculosis].
Topics: Adult; Aminosalicylic Acids; Antitubercular Agents; Biopsy; Chemical and Drug Induced Liver Injury; | 1965 |